Search

進行前立腺癌を封筒法で2群に分け, L群はテガフールを含む内分泌化学療法にレンチナンを併用, C群は, レンチナン(-)以外はL群と同様の治療を行った。L群33例の5年生存率43%, 50%生存期間は48ヵ月, C群36例の5年生存率は29%, 50%生存期間は35ヵ月で, L群は有意(P, A prospective, randomized multi-center study was conducted to assess the clinical effectiveness of Lentinan, an immunomodulatory agent, in the metastatic prostate cancer. Of seventy-five patients enrolled from July 1987 to June 1992, 69 were eligible. All patients received hormonal therapy and chemotherapy using Tegafur p.o. at a dose of 400-800 mg/day. While 33 patients received Lentinan i.m. for at least three months, the other 36 did not. The dose of Lentinan was 2 mg weekly for inpatients and 4 mg every other week for outpatients. The mean age of treated and control patients was 70 (range; 53-83) and 71 (range; 50-86), respectively. The 50% survival length of treated and control patients was 48 and 35 months, respectively. The five-year survival rate of treated patients was 43% according to the Kaplan-Meier method, while that of control patients was 29% (p < 0.05). We conclude that Lentinan is effective in metastatic prostate cancer when incorporated into hormonochemotherapy.

17歳から82歳までの45例の先行薬剤無効の複雑性尿路感染症症例に対し, IPM/CSを0.5 g×2/日, 5日間投与を行い, その薬剤効果を検討した.薬剤投与による起炎菌の消失率をみると, グラム陽性菌では79%に, 陰性菌では94%にみられた.総合臨床効果についてみると著効は8例, 有効は31例にみられ, 有効率87%であった.副作用は6例にみられたが, いずれも軽微であった, Clinical efficacy of sodium imipenem/cilastatin was studied on 45 patients with complicated urinary tract infections, on whom prior antimicrobial agents were ineffective. A 0.5g dose of IPM/CS was administered by drop infusion twice a day for 5 days. The clinical efficacy was evaluated according to the criteria of the Japanese UTI committee. Of a total of 65 strains, 29 strains of gram positive bacteria and 36 strains of gram negative bacteria, were detected as causative microbials. Bacteriologically, 23 strains of gram positive bacteria (79%) and 34 strains of gram negative bacteria (94%) were eradicated following the treatment. S. aureus, E. faecalis and Flavobacterium sp. were less sensitive to IPM/CS. Overall clinical effectiveness rate of IPM/CS in the present study was 87%. Adverse drug side effects were observed in six patients, namely they were eruption, headache and slight elevation of serum transaminase. These findings suggest that IPM/CS is an effective agent for the treatment of complicated UTI even when the prior medicine was ineffective.

単純性尿路感染症75症例, 複雑性尿路感染症63症例に対しTFLX (450 mg/day, 分3)を投与した.1)単純性では全例に起炎菌の消失をみ, 100%の臨床効果がえられたが, グラム陽性菌に菌交代したものが3例みられた.2)複雑性では起炎菌の消失は38例にみられ, 菌存続は16例に, 菌交代は9例にみられた.総合臨床効果は46例にみられたが, P. aeruginosa, S. marcescensを起炎菌とするものには効果が低かった.3)副作用はTFLX投与の161例につき検討し, 2例に腹部症状をみたが, いずれも軽微であり重篤なものはなかった.以上より尿路感染症症例に対するTFLX投与は安全でかつ有用な治療法であると思われた, We evaluated a newly developed quinolone agent, tosurofloxacin (TFLX), for its safety and clinical efficacy on patients with urinary tract infections (UTI). Among 138 cases satisfying the UTI criteria, 75 cases were acute simple UTI and 63 cases were chronic complicated UTI. In principle, a daily dose of 450 mg of TFLX was administered for 3 days and for 5 days for acute simple UTI and for chronic complicated UTI, respectively. Clinical efficacy of TFLX in these cases was evaluated according to the criteria of Japanese UTI committee. Bacteriologically, all 80 strains isolated from acute simple UTI were eradicated following TFLX administration. However, 2 gram positive strains and 1 gram negative strain, appeared following the treatment. In cases of chronic complicated UTI, 29 out of 32 gram positive strains and 29 out of 44 gram negative strains were eradicated. Among the isolated strains, P. aeruginosa and S. marcescens persisted, which suggests that they were less sensitive to TFLX. Overall clinical effectiveness rate of TFLX on acute simple UTI was 100%, while that on chronic complicated UTI was 73%. Adverse drug side effects were minimum, stomach discomfort and constipation was observed in one case each. These findings indicate that TFLX is a useful agent for the treatment of both simple and complicated UTI.